BioSpace News Archive

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes

Honduras President Juan Orlando Hernández announced the immediate roll out of an economic aid plan to fully address the main needs of the population amid the sanitary emergency caused by COVID-19 and its consequences.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

The application seeks approval of a new, additional formulation of Xofluza as granules for oral suspension for people one year of age and older with influenza

The shareholders in Moberg Pharma AB are hereby convened to the Extraordinary General Meeting on Tuesday, 28 April 2020 at 4:30 p.m. in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden.

Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth quarter and full year of 2019.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a corporate update. “2019 was a productive year for the Company with the acquisition of ALT-801, a supplemental award for the development of NasoShield from BARDA, and the advancement of ALT-702 as a preclinical program,” said Vipin K. Garg, Ph.D., President and Chief Executive Offi

AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020 Company announces clinical trial updates for clear cell renal cell carcinoma and IgA Nephropathy studies Current cash runway expected to fund company into 2022 HOUSTON, March 27, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threat

Spectral Medical Inc., today announced its financial results for the fourth quarter and for the year ended December 31, 2019. Financial Review Revenue for the three months ended December 31, 2019 was $746,000 compared to $1,864,000 for the same three-month period last year. Revenue for the year ended December 31, 2019 was $2,868,000 compared

Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, today announced the appointment of Chief Financial Officer Mr. Ryan Maarschalk, Bsc, CPA.